StreetInsider.com News Articles

Form 4 Relay Therapeutics, Inc. For: Aug 26 Filed by: Rahmer Peter

Fri, 28 Aug 2026 16:44:00 -0400

si-local-file:///var/storage/secattach/20260828/26998716.html

Form 4 Relay Therapeutics, Inc. For: Aug 26 Filed by: Rahmer Peter

Fri, 28 Aug 2026 16:44:00 -0400

si-local-file:///var/storage/secattach/20260828/26998716.html

Form 4 Relay Therapeutics, Inc. For: Aug 25 Filed by: SB INVESTMENT ADVISERS (UK) LTD

Fri, 28 Aug 2026 09:02:00 -0400

si-local-file:///var/storage/secattach/20260828/26993553.html

Form 4 Relay Therapeutics, Inc. For: Aug 25 Filed by: SB INVESTMENT ADVISERS (UK) LTD

Fri, 28 Aug 2026 09:02:00 -0400

si-local-file:///var/storage/secattach/20260828/26993553.html

Form 144 Relay Therapeutics, Inc. Filed by: Rahmer Peter

Wed, 26 Aug 2026 16:16:00 -0400

si-local-file:///var/storage/secattach/20260826/26981986.html

Form 144 Relay Therapeutics, Inc. Filed by: Rahmer Peter

Wed, 26 Aug 2026 16:16:00 -0400

si-local-file:///var/storage/secattach/20260826/26981986.html

Form 144 Relay Therapeutics, Inc. Filed by: SVF Pauling (Cayman) Ltd

Tue, 25 Aug 2026 19:43:00 -0400

si-local-file:///var/storage/secattach/20260825/26976074.html

Form 144 Relay Therapeutics, Inc. Filed by: SVF Pauling (Cayman) Ltd

Tue, 25 Aug 2026 19:43:00 -0400

si-local-file:///var/storage/secattach/20260825/26976074.html

Relay Therapeutics (RLAY) PT Raised to $29 at H.C. Wainwright

Thu, 20 Aug 2026 06:55:45 -0400

(Updated - August 20, 2026 6:55 AM EDT)

H.C. Wainwright analyst Robert Burns raised the price target on Relay Therapeutics (NASDAQ: RLAY) to $29.00 (from $28.00) while maintaining a Buy rating.

The analyst commented: "For 2Q26, Relay recorded a net loss of $0.41 per share, relatively in line with our original net loss estimate of $0.37 per share. R&D and SG&A expenses were $76.5M and $14.7M, respectively, vs. our estimates of $72.0M and $11.5M. We now project a full-year 2026 net loss of $1.57 per share. Relay ended 2Q26 with $910.9M in cash, which should span numerous key data catalysts, since these

Relay Therapeutics (RLAY) PT Raised to $29 at H.C. Wainwright

Thu, 20 Aug 2026 06:55:45 -0400

(Updated - August 20, 2026 6:55 AM EDT)

H.C. Wainwright analyst Robert Burns raised the price target on Relay Therapeutics (NASDAQ: RLAY) to $29.00 (from $28.00) while maintaining a Buy rating.

Form 4 Relay Therapeutics, Inc. For: Aug 17 Filed by: Patel Sanjiv

Tue, 18 Aug 2026 16:18:00 -0400

si-local-file:///var/storage/secattach/20260818/26944521.html

Form 4 Relay Therapeutics, Inc. For: Aug 17 Filed by: Patel Sanjiv

Tue, 18 Aug 2026 16:18:00 -0400

si-local-file:///var/storage/secattach/20260818/26944521.html

Form 4 Relay Therapeutics, Inc. For: Aug 14 Filed by: Catinazzo Thomas

Tue, 18 Aug 2026 16:17:00 -0400

si-local-file:///var/storage/secattach/20260818/26944499.html

Form 4 Relay Therapeutics, Inc. For: Aug 14 Filed by: Catinazzo Thomas

Tue, 18 Aug 2026 16:17:00 -0400

si-local-file:///var/storage/secattach/20260818/26944499.html

Form SCHEDULE 13G/A Relay Therapeutics, Inc. Filed by: Commodore Capital LP

Fri, 14 Aug 2026 16:18:00 -0400

si-local-file:///var/storage/secattach/20260814/26930726.html

Form SCHEDULE 13G/A Relay Therapeutics, Inc. Filed by: Commodore Capital LP

Fri, 14 Aug 2026 16:18:00 -0400

si-local-file:///var/storage/secattach/20260814/26930726.html

Relay Therapeutics (RLAY) PT Raised to $31 at JPMorgan

Fri, 14 Aug 2026 09:04:27 -0400

JPMorgan analyst Priyanka Grover raised the price target on Relay Therapeutics (NASDAQ: RLAY) to $31.00 (from $28.00) while maintaining a Overweight rating.

Form SCHEDULE 13G/A Relay Therapeutics, Inc. Filed by: PERCEPTIVE ADVISORS LLC

Mon, 10 Aug 2026 16:00:00 -0400

si-local-file:///var/storage/secattach/20260810/26897542.html

Form SCHEDULE 13G/A Relay Therapeutics, Inc. Filed by: PERCEPTIVE ADVISORS LLC

Mon, 10 Aug 2026 16:00:00 -0400

si-local-file:///var/storage/secattach/20260810/26897542.html

Relay Therapeutics (RLAY) PT Raised to $26 at Citizens on Zovega Data

Mon, 10 Aug 2026 04:12:52 -0400

Citizens analyst Silvan Turkcan raised the price target on Relay Therapeutics (NASDAQ: RLAY) to $26.00 (from $21.00) while maintaining a Market Outperform rating.

The analyst commented, "A lot of progress makes BC a very interesting arena, and we view RLAY as one of the players that is emerging with potential for a backbone drug. In 2L, we believe zovega has already generated a strong clinical data set, with a pooled efficacy/safety dataset comprising 109 patients (~40% of Ph3 size), which increases the confidence in the Phase 3 readout and final profile. Regarding front line, we view the early triplet update as

Relay Therapeutics (RLAY) PT Raised to $26 at Citizens on Zovega Data

Mon, 10 Aug 2026 04:12:52 -0400

Citizens analyst Silvan Turkcan raised the price target on Relay Therapeutics (NASDAQ: RLAY) to $26.00 (from $21.00) while maintaining a Market Outperform rating.

Form SCHEDULE 13G/A Relay Therapeutics, Inc. Filed by: FMR LLC

Fri, 07 Aug 2026 11:20:00 -0400

si-local-file:///var/storage/secattach/20260807/26889392.html

Form SCHEDULE 13G/A Relay Therapeutics, Inc. Filed by: FMR LLC

Fri, 07 Aug 2026 11:20:00 -0400

si-local-file:///var/storage/secattach/20260807/26889392.html

Relay Therapeutics (RLAY) PT Raised to $30 at Barclays

Fri, 07 Aug 2026 04:55:38 -0400

Barclays analyst Peter Lawson raised the price target on Relay Therapeutics (NASDAQ: RLAY) to $30.00 (from $27.00) while maintaining a Overweight rating.

Guggenheim Reiterates Buy Rating on Relay Therapeutics (RLAY)

Fri, 07 Aug 2026 02:08:19 -0400

Guggenheim analyst Brad Canino reiterated a Buy rating and $26.00 price target on Relay Therapeutics (NASDAQ: RLAY)

The analyst comments: “RLAY continues to execute the Phase 3 ReDiscover-2 study of zovega + fulvestrant in 2L+ PIK3CAm HR+ mBC with an enrollment update reiterated by YE26. Importantly, management continues to advance zovegalisib into 1L following recent selection of the zovega + atirmociclib + ET triplet for Phase 3, supported by the initial phase 1b that showed activity with high dose intensity for all drugs in the regimen, which is crucial for the multi-year 1L treatment durations that are expected. RLAY guided to